{"id":4132,"date":"2026-11-03T09:00:00","date_gmt":"2026-11-03T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4132"},"modified":"2026-11-07T16:07:55","modified_gmt":"2026-11-07T20:07:55","slug":"sanofi-ends-partnered-stat6-degrader-program","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4132","title":{"rendered":"Sanofi Ends Partnered STAT6 Degrader Program"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"768\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261106_Nurix_Therapeutics_Technology_and_Modalities-768x768.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4138\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261106_Nurix_Therapeutics_Technology_and_Modalities-768x768.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261106_Nurix_Therapeutics_Technology_and_Modalities-300x300.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261106_Nurix_Therapeutics_Technology_and_Modalities-1024x1024.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261106_Nurix_Therapeutics_Technology_and_Modalities-150x150.png 150w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261106_Nurix_Therapeutics_Technology_and_Modalities.png 1254w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>Nurix Therapeutics; Sanofi<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>Partner program discontinuation<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>Targeted protein degrader (oral)<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>SAR448272<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>STAT6<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Type 2 inflammation<\/p>\n<h4>Summary<\/h4>\n<p>Previously missed November 3 primary disclosure: Sanofi decided to stop the Phase 1 trial and terminate SAR448272, an oral STAT6 degrader licensed from Nurix. The cause was not given in the issuer announcement; the outcome must not be generalized to all STAT6 degraders.<\/p>\n<p>Nurix said future SAR448272 milestones and royalties will no longer be expected. Other collaboration programs remain eligible. Nurix maintained its previously issued cash-runway guidance and separately listed BTK, CBL-B and IRAK4 clinical programs.<\/p>\n<h4>Deep Analysis<\/h4>\n<p><strong>Interpretation A:<\/strong> the termination may reflect a molecule-specific nonclinical or safety concern, but the primary announcement did not disclose the reason.<\/p>\n<p><strong>Interpretation B:<\/strong> it may represent portfolio prioritization unrelated to target validity. Both remain plausible. A Sanofi technical disclosure, toxicology, exposure data and competitor STAT6 clinical outcomes would distinguish them. Degrader tissue penetration, off-target proteomics, E3-ligase biology and immunologic suppression remain key translational tests.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>STAT6 transduces IL-4\/IL-13 signaling in type 2 inflammation. SAR448272 was designed to recruit degradation machinery to eliminate STAT6 protein; it had entered first-in-human testing.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>This is a partner discontinuation, not a reported failed efficacy trial.<\/li>\n<li>The precise reason remains undisclosed in the primary release.<\/li>\n<li>Do not infer Nurix financial distress from the decision.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>The program loss is material to partnered degradation economics; no class-wide efficacy or safety conclusion is supported.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 4 of 5. Signal Direction: negative for this asset, uncertain for the class. Confidence in Facts: high. Confidence in Interpretation: low.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Previously missed November 3 primary disclosure: Sanofi decided to stop the Phase 1 trial and terminate SAR448272, an oral STAT6 degrader licensed from Nurix. The cause was not given in the issuer announcement; the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4138,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[91,29,818],"class_list":["post-4132","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology-modalities","tag-nurix-therapeutics","tag-sanofi","tag-stat6"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4132","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4132"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4132\/revisions"}],"predecessor-version":[{"id":4154,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4132\/revisions\/4154"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4138"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4132"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4132"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4132"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}